Literature DB >> 3675423

Economic impact of Mycoplasma gallisepticum and M. synoviae in commercial layer flocks.

H O Mohammed1, T E Carpenter, R Yamamoto.   

Abstract

An egg-production function was constructed, using data collected from 366 commercial layer flocks in California, to predict the impact of Mycoplasma gallisepticum (MG) and M. synoviae (MS) on egg production while controlling for confounding factors. In the first and second cycles, respectively, an MG-infected flock produced 12 and 5 fewer eggs per hen than an uninfected flock. Flocks that became infected with MG after F-strain vaccination produced 6 eggs/hen more than unvaccinated infected flocks in the first cycle, but no significant difference was observed between such groups in the second cycle. No association was found between MS-infection and egg production. Commercial layer producers in Southern California lost an estimated 127 million eggs because of MG in 1984. This lost egg production and associated MG-control-program costs amounted to an estimated financial loss of approximately $7 million. This represented a loss of approximately $6 million in consumer surplus.

Entities:  

Mesh:

Year:  1987        PMID: 3675423

Source DB:  PubMed          Journal:  Avian Dis        ISSN: 0005-2086            Impact factor:   1.577


  11 in total

1.  In vivo pharmacokinetic/pharmacodynamic profiles of valnemulin in an experimental intratracheal Mycoplasma gallisepticum infection model.

Authors:  Xia Xiao; Jian Sun; Tao Yang; Xi Fang; Dong Wu; Yan Q Xiong; Jie Cheng; Yi Chen; Wei Shi; Ya-Hong Liu
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

2.  In vitro cell invasion of Mycoplasma gallisepticum.

Authors:  F Winner; R Rosengarten; C Citti
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

3.  Eggshell apex abnormalities associated with Mycoplasma synoviae infection in layers.

Authors:  Eun-Ok Jeon; Jong-Nyeo Kim; Hae-Rim Lee; Bon-Sang Koo; Kyeong-Cheol Min; Moo-Sung Han; Seung-Baek Lee; Yeon-Ji Bae; Jong-Suk Mo; Sun-Hyung Cho; Chang-Hee Lee; In-Pil Mo
Journal:  J Vet Sci       Date:  2014-06-20       Impact factor: 1.672

4.  Structural and functional characterization of an organic hydroperoxide resistance protein from Mycoplasma gallisepticum.

Authors:  Cheryl Jenkins; Ram Samudrala; Steven J Geary; Steven P Djordjevic
Journal:  J Bacteriol       Date:  2008-01-11       Impact factor: 3.490

5.  Comparative Study of Serological Tests for Mycoplasma synoviae Diagnosis in Commercial Poultry Breeders.

Authors:  R L Luciano; A L S P Cardoso; G F Z Stoppa; A M I Kanashiro; A G M de Castro; E N C Tessari
Journal:  Vet Med Int       Date:  2011-04-03

6.  Epidemiological investigation of Mycoplasma Synoviae in native chicken breeds in China.

Authors:  Shi-Kai Sun; Xin Lin; Feng Chen; Ding-Ai Wang; Jun-Peng Lu; Jian-Ping Qin; Ting-Rong Luo
Journal:  BMC Vet Res       Date:  2017-04-26       Impact factor: 2.741

7.  Transcriptomic Analysis of Long-Term Protective Immunity Induced by Vaccination With Mycoplasma gallisepticum Strain ts-304.

Authors:  Sathya N Kulappu Arachchige; Neil D Young; Anna Kanci Condello; Oluwadamilola S Omotainse; Amir H Noormohammadi; Nadeeka K Wawegama; Glenn F Browning
Journal:  Front Immunol       Date:  2021-02-02       Impact factor: 7.561

8.  Pharmacokinetic/Pharmacodynamic Profiles of Tiamulin in an Experimental Intratracheal Infection Model of Mycoplasma gallisepticum.

Authors:  Xia Xiao; Jian Sun; Tao Yang; Xi Fang; Jie Cheng; Yan Q Xiong; Ya-Hong Liu
Journal:  Front Vet Sci       Date:  2016-09-06

Review 9.  Live Bacterial Prophylactics in Modern Poultry.

Authors:  Graham A J Redweik; Jared Jochum; Melha Mellata
Journal:  Front Vet Sci       Date:  2020-10-28

10.  Effects of dietary Original XPC on selected blood variables in layer pullets challenged with Mycoplasma gallisepticum,.

Authors:  E D Peebles; K E C Elliott; S L Branton; J D Evans; S A Leigh; E J Kim; H A Olanrewaju; G T Pharr; H O Pavlidis; P D Gerard
Journal:  Poult Sci       Date:  2020-06-20       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.